The Food and Drug Administration (FDA) has granted Fast Track Designation to AVB-S6-500 (Aravive Biologics), an investigational treatment for platinum-resistant recurrent ovarian cancer

AVB-S6-500 is a novel, high-affinity Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway, which research has found to be key in promoting tumor growth and metastases. A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events. In addition, a dose-related reduction in circulating free GAS6 was noted in the trial; a reduction in this biomarker has been associated with anti-tumor activity in preclinical studies.

‘We look forward to initiating the Phase 1b portion of our planned Phase 1b/2 study combining AVB-S6-500 with standard-of care therapies in patients with platinum-resistant ovarian cancer before the end of the year,” said Ray Tabibiazar, MD, Executive Chairman of Aravive Biologics. 

Continue Reading

Related Articles

For more information visit

This article originally appeared on MPR